Biomarkers for Diagnosis of Lung Cancer

NCT ID: NCT02050100

Last Updated: 2017-05-12

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

300 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-01-31

Study Completion Date

2015-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study goal is to collect blood samples from individuals at risk for lung cancer in order to identify protein markers for diagnosis of lung cancer in the Chinese population.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer Lung Neoplasm

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lung Cancer

Early-late stage primary lung cancer

No interventions assigned to this group

Lung Neoplasm

Benign non-calcified pulmonary nodules

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adults ≥ 18 years of age
* Patients referred to pulmonologists, oncologists, or thoracic surgeons for diagnosis of suspicious pulmonary nodules as either lung cancer or benign and undergoing bronchoscopic biopsy
* Patients will be enrolled if the result of the bronchoscopic biopsy is a diagnosis of NSCLC or benign pulmonary nodule
* Cases: Patients with untreated non-small cell lung cancer, i.e. primary lung adenocarcinoma or squamous cell carcinoma of early
* Computed tomography or X-Ray is available and shows a suspicious pulmonary nodule
* A biopsy or surgical resection to clarify the nature of the lung nodule is available (NSCLC or benign, including histological diagnosis) in both groups
* Controls: Patients must be available for a 6 month follow-up to confirm benign diagnosis
* A serum and plasma sample was collected prior to any treatment of the lung nodule beyond biopsy
* No other cancer diagnosis in the last 5 years excluding non-melanoma skin cancer
* Patients must be fully informed of the investigational nature of the procedure and sign an informed consent.

Exclusion Criteria

* Prior treatment for lung cancer by chemotherapy or surgery (excluding biopsy)
* Patients with benign nodules who are not able or willing to have a 6-month follow-up visit to confirm benign diagnosis
* Diagnosis or treatment of other cancer in the last 5 years excluding non-melanoma skin cancer. In the judgment of the clinical investigator, patients who are likely to be non compliant or uncooperative during the study.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SK Medical (Beijing) Co., Ltd.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Chunxue Bai, M.D, Ph.D.

Role: PRINCIPAL_INVESTIGATOR

Zhongshan Hospital Fudan Universit

Xiaoju Zhang, M.D.

Role: PRINCIPAL_INVESTIGATOR

Henan Provincial People's Hospital

Muyun Zhu, M.D.

Role: PRINCIPAL_INVESTIGATOR

Northern Jiangsu People's Hospital

Kai Wang, MD

Role: PRINCIPAL_INVESTIGATOR

The Second Affliated Hospital of Zhejiang University School of Medicine

Zuke Xiao, MD

Role: PRINCIPAL_INVESTIGATOR

Jiangxi Provincial People's Hopital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Northern Jiangsu People's Hospital

Yangzhou, Jiangsu, China

Site Status

Jiangxi Provincial People's Hospital

Nanchang, Jiangxi, China

Site Status

The Second Affliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, China

Site Status

Zhongshan Hospital Fudan University

Shanghai, , China

Site Status

Henan province People's hospital

Zhengzhou, , China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

SKTCTCH0001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.